Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer

NCT05220098 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05220098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05220098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Lead sponsor
Takeda
Phase
Phase 1/2
Overall status
Terminated
Start date
April 21, 2022
Completion date
July 28, 2025
Enrollment
69 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable locally advanced or metastatic cancer